title: Efficacy and safety of neuroleptics in behavioral disorders associated with dementia.
abstract: BACKGROUND
  Neuroleptics are commonly used to treat behavioral disorders associated with dementia. However, their safety and efficacy have not been well established in these patients.
  
  
  METHODS
  A meta-analysis of randomized, controlled (either placebo or active drug), double-blind trials published since 1966 (N = 16; 499 treated, 112 active controls, and 123 placebo) was conducted. Data were collected on proportion of patients with clinically significant improvement, significant side effects, and dropout rates.
  
  
  RESULTS
  Pooled mean percentages of patients who improved (95% CI): all neuroleptics, 64% (54% to 74%); low potency, 63% (54% to 72%); moderate potency, 70% (56% to 85%); moderate-high potency, 62% (49% to 75%); and high potency, 69% (49% to 90%). Thus, no differences in efficacy existed between different potencies of neuroleptics. Therapeutic effect (neuroleptic minus placebo) was only 26% (14% to 38%). Treatment-emergent side effects were more common for neuroleptics vs. placebo (mean difference = 25%, 13% to 37%), but pooled mean dropout rates were not different (mean difference = 4%, -7% to 14%). Neither weighting by clinical trial quality (3 raters; weighted agreement, 83% to 92%) nor exclusion of poor quality trials changed the results.
  
  
  CONCLUSIONS
  Neuroleptics have small but significant efficacy over placebo in this population, and the efficacy rate is equivalent to the side effect rate. Comparing different neuroleptics shows they have similar efficacy, side effects, and dropout rates. Further study to determine more specific drug-responsive behaviors is needed to maximize benefits of these drugs.
authors.affiliation: Psychopharmacology Research Program, Sunnybrook Health Science Centre, and the Department of Pharmacology, University of Toronto, Ontario, Canada.
authors.forename: K L
authors.initials: KL
authors.lastname: Lanctôt
authors.forename: T S
authors.initials: TS
authors.lastname: Best
authors.forename: N
authors.initials: N
authors.lastname: Mittmann
authors.forename: B A
authors.initials: BA
authors.lastname: Liu
authors.forename: P I
authors.initials: PI
authors.lastname: Oh
authors.forename: T R
authors.initials: TR
authors.lastname: Einarson
authors.forename: C A
authors.initials: CA
authors.lastname: Naranjo
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003704:Dementia / Q000150:complications* / Q000523:psychology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D010352:Patient Dropouts; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010919:Placebos